517 related articles for article (PubMed ID: 26609865)
1. Recent advances in siRNA delivery.
Sarisozen C; Salzano G; Torchilin VP
Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
[TBL] [Abstract][Full Text] [Related]
2. [Types of non-viral delivery systems of small interfering RNA].
Glebova KV; Marakhonov AV; Baranova AV; Skoblov MIu
Mol Biol (Mosk); 2012; 46(3):387-401. PubMed ID: 22888629
[TBL] [Abstract][Full Text] [Related]
3. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
4. [Advance in the study of targeting delivery system for siRNA mediated by aptamers].
Wang XL; Wang QQ; Song HF
Yao Xue Xue Bao; 2012 Jul; 47(7):850-5. PubMed ID: 22993847
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.
Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269550
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic siRNAs and non-viral systems for their delivery].
Glebova KV; Marakhonov AV; Baranova AV; Skoblov MIu
Mol Biol (Mosk); 2012; 46(3):371-86. PubMed ID: 22888628
[TBL] [Abstract][Full Text] [Related]
7. A review of nanocarriers for the delivery of small interfering RNA.
Kesharwani P; Gajbhiye V; Jain NK
Biomaterials; 2012 Oct; 33(29):7138-50. PubMed ID: 22796160
[TBL] [Abstract][Full Text] [Related]
8. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
[TBL] [Abstract][Full Text] [Related]
10. SiRNA delivery: challenges and role of carrier systems.
Shegokar R; Al Shaal L; Mishra PR
Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
[TBL] [Abstract][Full Text] [Related]
11. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
12. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
Akhtar S; Benter I
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
[TBL] [Abstract][Full Text] [Related]
13. Delivering siRNA with Dendrimers: In Vivo Applications.
Leiro V; Santos SD; Pego AP
Curr Gene Ther; 2017; 17(2):105-119. PubMed ID: 28494741
[TBL] [Abstract][Full Text] [Related]
14. Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.
Scherman D; Rousseau A; Bigey P; Escriou V
Gene Ther; 2017 Mar; 24(3):151-156. PubMed ID: 28121307
[TBL] [Abstract][Full Text] [Related]
15. Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes.
Singh Y; Tomar S; Khan S; Meher JG; Pawar VK; Raval K; Sharma K; Singh PK; Chaurasia M; Surendar Reddy B; Chourasia MK
J Control Release; 2015 Dec; 220(Pt A):368-387. PubMed ID: 26528900
[TBL] [Abstract][Full Text] [Related]
16. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
17. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
18. Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological action.
Dzmitruk V; Szulc A; Shcharbin D; Janaszewska A; Shcharbina N; Lazniewska J; Novopashina D; Buyanova M; Ionov M; Klajnert-Maculewicz B; Gómez-Ramirez R; Mignani S; Majoral JP; Muñoz-Fernández MA; Bryszewska M
Int J Pharm; 2015 May; 485(1-2):288-94. PubMed ID: 25796120
[TBL] [Abstract][Full Text] [Related]
19. Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (A). Mechanisms of interaction.
Ionov M; Lazniewska J; Dzmitruk V; Halets I; Loznikova S; Novopashina D; Apartsin E; Krasheninina O; Venyaminova A; Milowska K; Nowacka O; Gomez-Ramirez R; de la Mata FJ; Majoral JP; Shcharbin D; Bryszewska M
Int J Pharm; 2015 May; 485(1-2):261-9. PubMed ID: 25791760
[TBL] [Abstract][Full Text] [Related]
20. Knocking down barriers: advances in siRNA delivery.
Whitehead KA; Langer R; Anderson DG
Nat Rev Drug Discov; 2009 Feb; 8(2):129-38. PubMed ID: 19180106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
